Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy

Current Cardiology Reviews

Volumn 6, Issue 4, 2010, Pages 280-290

  Watanabe, Kenichi ^a   Thandavarayan, Rajarajan A ^a   Harima, Meilei ^a   Sari, Flori R ^a   Gurusamy, Narasimman ^b   Veeraveedu, Punniyakoti T ^a   Mito, Sayaka ^a   Arozal, Wawaimuli ^a   Sukumaran, Vijayakumar ^a   Laksmanan, Arun Prasath ^a   Soetikno, Vivian ^a   Kodama, Makoto ^c   Aizawa, Yoshifusa ^c  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Apoptosis; Cardiomyopathy; Diabetes mellitus; Hypertrophy; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; APOPTOSIS SIGNAL REGULATING KINASE 1; GLYCOGEN SYNTHASE KINASE 3BETA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C; STREPTOZOCIN; TEMPOL;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DISEASE COURSE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; METABOLIC DISORDER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; SYSTOLIC DYSFUNCTION;

EID: 78651322164     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310793566145     Document Type: Article

References (163)

1. Bauters C, Lamblin N, McFadden EP, Van Belle E, Millaire A, deGroote P. Influence of diabetes mellitus on heart failure risk andoutcome. Cardiovasc Diabetol 2003; 2: 1.
2. Bell DS. Diabetic cardiomyopathy. A unique entity or a complicationof coronary artery disease? Diabetes Care 1995; 18: 708-14.
3. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes forthe development of a cardiomyopathy. Cardiovasc Res 1992; 26: 913-22.
4. Spector KS. Diabetic cardiomyopathy. Clin Cardiol 1998; 21: 885-7.
5. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabeticglomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
6. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Prog CardiovascDis 1985; 27: 255-70.
7. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestiveheart failure. Further knowledge needed. Eur Heart J 1999; 20: 789-95.
8. Marra G, Cotroneo P, Pitocco D, et al. Early increase of oxidativestress and reduced antioxidant defenses in patients with uncomplicatedtype 1 diabetes: a case for gender difference. Diabetes Care 2002; 25: 370-5.
9. Penckofer S, Schwertz D, Florczak K. Oxidative stress and cardiovasculardisease in type 2 diabetes: the role of antioxidants and prooxidants. J Cardiovasc Nurs 2002; 16: 68-85.
10. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidativestress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339-52.
11. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation byearly glycation products: a mechanism for accelerated atherogenesisin diabetes. Biochem Biophys Res Commun 1990; 173: 932-9.
12. Baynes JW. Role of oxidative stress in development of complicationsin diabetes. Diabetes 1991; 40: 405-12.
13. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxiaand diabetic complications. Diabetes 1993; 42: 801-13.
14. Sano T, Umeda F, Hashimoto T, Nawata H, Utsumi H. Oxidativestress measurement by in vivo electron spin resonance spectroscopyin rats with streptozotocin-induced diabetes. Diabetologia 1998; 41: 1355-60.
15. Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase Cdependentincrease in reactive oxygen species (ROS) production invascular tissues of diabetes: role of vascular NAD(P)H oxidase. JAm Soc Nephrol 2003; 14: S227-32.
16. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543-67.
17. Cai L, Kang YJ. Cell death and diabetic cardiomyopathy. CardiovascToxicol 2003; 3: 219-28.
18. Li X, Xu Z, Li S, Rozanski GJ. Redox regulation of Ito remodelingin diabetic rat heart. Am J Physiol Heart Circ Physiol 2005; 288: H1417-24.
19. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: abrief review. Cardiovasc Toxicol 2001; 1: 181-93.
20. Pang Y, Hunton DL, Bounelis P, Marchase RB. Hyperglycemiainhibits capacitative calcium entry and hypertrophy in neonatalcardiomyocytes. Diabetes 2002; 51: 3461-7.
21. Ligeti L, Szenczi O, Prestia CM, et al. Altered calcium handling isan early sign of streptozotocin-induced diabetic cardiomyopathy. Int J Mol Med 2006; 17: 1035-43.
22. Finck BN, Han X, Courtois M, et al. A critical role for PPARalphamediatedlipotoxicity in the pathogenesis of diabetic cardiomyopathy:modulation by dietary fat content. Proc Natl Acad Sci USA 2003; 100: 1226-31.
23. Diwan A, Tran T, Misra A, Mann DL. Inflammatory mediators andthe failing heart: a translational approach. Curr Mol Med 2003; 3: 161-82.
24. Brownlee M. The pathobiology of diabetic complications: a unifyingmechanism. Diabetes 2005; 54: 1615-25.
25. Gurusamy N, Watanabe K, Ma M, et al. Dominant negative 14-3-3promotes cardiomyocyte apoptosis in early stage of type I diabetesmellitus through activation of JNK. Biochem Biophys Res Commun 2004; 320: 773-80.
26. Gurusamy N, Watanabe K, Ma M, et al. Inactivation of 14-3-3protein exacerbates cardiac hypertrophy and fibrosis through enhancedexpression of protein kinase C beta 2 in experimental diabetes. Biol Pharm Bull 2005; 28: 957-62.
27. Szkudelski T. The mechanism of alloxan and streptozotocin actionin B cells of the rat pancreas. Physiol Res 2001; 50: 537-46.
28. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessmentof cardiac function in diabetic db/db and transgenicdb/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 2002; 283: H976-82.
29. Ganguly PK, Thliveris JA, Mehta A. Evidence against the involvementof nonenzymatic glycosylation in diabetic cardiomyopathy. Metabolism 1990; 39: 769-73.
30. Rajan SK, Gokhale SM. Cardiovascular function in patients withinsulin-dependent diabetes mellitus: a study using noninvasivemethods. Ann NY Acad Sci 2002; 958: 425-30.
31. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW. Diastolicabnormalities in young asymptomatic diabetic patients assessedby pulsed Doppler echocardiography. J Am Coll Cardiol 1988; 12: 114-20.
32. Dent CL, Bowman AW, Scott MJ, et al. Echocardiographic characterizationof fundamental mechanisms of abnormal diastolic fillingin diabetic rats with a parameterized diastolic filling formalism. JAm Soc Echocardiogr 2001; 14: 1166-72.
33. Flarsheim CE, Grupp IL, Matlib MA. Mitochondrial dysfunctionaccompanies diastolic dysfunction in diabetic rat heart. Am JPhysiol 1996; 271: H192-202.
34. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolicdysfunction in normotensive men with well-controlled type 2 diabetes:importance of maneuvers in echocardiographic screening forpreclinical diabetic cardiomyopathy. Diabetes Care 2001; 24: 5-10.
35. Joffe, II, Travers KE, Perreault-Micale CL, et al. Abnormal cardiacfunction in the streptozotocin-induced non-insulin-dependent diabeticrat: noninvasive assessment with doppler echocardiographyand contribution of the nitric oxide pathway. J Am Coll Cardiol 1999; 34: 2111-9.
36. Wold LE, Relling DP, Colligan PB, et al. Characterization of contractilefunction in diabetic hypertensive cardiomyopathy in adultrat ventricular myocytes. J Mol Cell Cardiol 2001; 33: 1719-26.
37. Hoit BD, Castro C, Bultron G, Knight S, Matlib MA. Noninvasiveevaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats. J Card Fail 1999; 5: 324-33.
38. Hayashi K, Okumura K, Matsui H, et al. Involvement of 1,2-diacylglycerol in improvement of heart function by etomoxir indiabetic rats. Life Sci 2001; 68: 1515-26.
39. Vered A, Battler A, Segal P, et al. Exercise-induced left ventriculardysfunction in young men with asymptomatic diabetes mellitus(diabetic cardiomyopathy). Am J Cardiol 1984; 54: 633-7.
40. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathyin familial diabetes mellitus. J Clin Invest 1977; 60: 884-99.
41. Raev DC. Which left ventricular function is impaired earlier in theevolution of diabetic cardiomyopathy? An echocardiographic studyof young type I diabetic patients. Diabetes Care 1994; 17: 633-9.
42. Friedman NE, Levitsky LL, Edidin DV, Vitullo DA, Lacina SJ, Chiemmongkoltip P. Echocardiographic evidence for impairedmyocardial performance in children with type I diabetes mellitus. Am J Med 1982; 73: 846-50.
43. Carlstrom S, Karlefors T. Haemodynamic studies on newly diagnoseddiabetics before and after adequate insulin treatment. BrHeart J 1970; 32: 355-8.
44. Howarth FC, Qureshi MA, White E, Calaghan SC. Cardiac microtubulesare more resistant to chemical depolymerisation in streptozotocin-induced diabetes in the rat. Pflugers Arch 2002; 444: 432-7.
45. Hileeto D, Cukiernik M, Mukherjee S, et al. Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev 2002; 18: 386-94.
46. Thompson EW. Quantitative analysis of myocardial structure ininsulin-dependent diabetes mellitus: effects of immediate and delayedinsulin replacement. Proc Soc Exp Biol Med 1994; 205: 294-305.
47. Shimada T. Correlation between metabolic and histopathologicalchanges in the myocardium of the KK mouse. Effect of diltiazemon the diabetic heart. Jpn Heart J 1993; 34: 617-26.
48. Naito J, Koretsune Y, Sakamoto N, et al. Transmural heterogeneityof myocardial integrated backscatter in diabetic patients withoutovert cardiac disease. Diabetes Res Clin Pract 2001; 52: 11-20.
49. Brown RA, Anthony MJ, Petrovski P, Ren J. The influence ofgender, diabetes, and acetaldehyde on the intrinsic contractile propertiesof isolated rat myocardium. Cardiovasc Toxicol 2001; 1: 35-42.
50. Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R. Quantitative approach to the histopathology of the biopsied rightventricular myocardium in patients with diabetes mellitus. HeartVessels 1985; 1: 43-7.
51. Chen V, Ianuzzo CD, Fong BC, Spitzer JJ. The effects of acute andchronic diabetes on myocardial metabolism in rats. Diabetes 1984; 33: 1078-84.
52. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucosemetabolism in noninsulin-dependent diabetes mellitus patientsevaluated by FDG-PET. J Nucl Med 1995; 36: 456-63.
53. Eckel J, Reinauer H. Insulin action on glucose transport in isolatedcardiac myocytes: signalling pathways and diabetes-induced alterations. Biochem Soc Trans 1990; 18: 1125-7.
54. Garvey WT, Hardin D, Juhaszova M, Dominguez JH. Effects ofdiabetes on myocardial glucose transport system in rats: implicationsfor diabetic cardiomyopathy. Am J Physiol 1993; 264: H837-44.
55. Russell RR, 3rd, Yin R, Caplan MJ, et al. Additive effects of hyperinsulinemiaand ischemia on myocardial GLUT1 and GLUT4translocation in vivo. Circulation 1998; 98: 2180-6.
56. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolismcauses cardiac dysfunction in perfused hearts from diabetic(db/db) mice. Am J Physiol Endocrinol Metab 2000; 279: E1104-13.
57. Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in substrate metabolism and effects of excess fatty acids inreperfused myocardium. Circ Res 1988; 62: 535-42.
58. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances indiabetic cardiomyopathy. Mol Cell Biochem 1998; 180: 53-7.
59. Nakayama H, Morozumi T, Nanto S, et al. Abnormal myocardialfree fatty acid utilization deteriorates with morphological changesin the hypertensive heart. Jpn Circ J 2001; 65: 783-7.
60. Malone JI, Schocken DD, Morrison AD, Gilbert-Barness E. Diabeticcardiomyopathy and carnitine deficiency. J Diabetes Complications 1999; 13: 86-90.
61. Pierce GN, Kutryk MJ, Dhalla NS. Alterations in Ca2+ binding byand composition of the cardiac sarcolemmal membrane in chronicdiabetes. Proc Natl Acad Sci USA 1983; 80: 5412-6.
62. Pierce GN, Dhalla NS. Sarcolemmal Na+-K+-ATPase activity indiabetic rat heart. Am J Physiol 1983; 245: C241-7.
63. Heyliger CE, Prakash A, McNeill JH. Alterations in cardiac sarcolemmalCa2+ pump activity during diabetes mellitus. Am JPhysiol 1987; 252: H540-4.
64. Bouchard RA, Bose D. Influence of experimental diabetes on sarcoplasmicreticulum function in rat ventricular muscle. Am JPhysiol 1991; 260: H341-54.
65. Penpargkul S, Fein F, Sonnenblick EH, Scheuer J. Depressed cardiacsarcoplasmic reticular function from diabetic rats. J Mol CellCardiol 1981; 13: 303-9.
66. Abe T, Ohga Y, Tabayashi N, et al. Left ventricular diastolic dysfunctionin type 2 diabetes mellitus model rats. Am J Physiol HeartCirc Physiol 2002; 282: H138-48.
67. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPaseimproves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002; 51: 1166-71.
68. Dillmann WH. Diabetes mellitus induces changes in cardiac myosinof the rat. Diabetes 1980; 29: 579-82.
69. Pierce GN, Dhalla NS. Heart mitochondrial function in chronicexperimental diabetes in rats. Can J Cardiol 1985; 1: 48-54.
70. Stroedter D, Schmidt T, Bretzel RG, Federlin K. Glucose metabolismand left ventricular dysfunction are normalized by insulin andislet transplantation in mild diabetes in the rat. Acta Diabetol 1995; 32: 235-43.
71. Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated bymyocardial ischemia and executed during reperfusion. J Mol CellCardiol 2000; 32: 197-208.
72. Guerra S, Leri A, Wang X, et al. Myocyte death in the failing humanheart is gender dependent. Circ Res 1999; 85: 856-66.
73. Sam F, Sawyer DB, Chang DL, et al. Progressive left ventricularremodeling and apoptosis late after myocardial infarction in mouseheart. Am J Physiol Heart Circ Physiol 2000; 279: H422-8.
74. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease inobese rats: implications for human obesity. Proc Natl Acad SciUSA 2000; 97: 1784-9.
75. Tea BS, Dam TV, Moreau P, Hamet P, deBlois D. Apoptosis duringregression of cardiac hypertrophy in spontaneously hypertensiverats. Temporal regulation and spatial heterogeneity. Hypertension 1999; 34: 229-35.
76. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death inhuman diabetes. Circ Res 2000; 87: 1123-32.
77. Fiordaliso F, Li B, Latini R, et al. Myocyte death in streptozotocininduceddiabetes in rats in angiotensin II- dependent. Lab Invest 2000; 80: 513-27.
78. Kajstura J, Fiordaliso F, Andreoli AM, et al. IGF-1 overexpressioninhibits the development of diabetic cardiomyopathy and angiotensinII-mediated oxidative stress. Diabetes 2001; 50: 1414-24.
79. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemiainducedapoptosis in mouse myocardium: mitochondrial cytochromeC-mediated caspase-3 activation pathway. Diabetes 2002; 51: 1938-48.
80. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102: 470-9.
81. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophyand failure. N Engl J Med 1999; 341: 1276-83.
82. Yamazaki T, Komuro I, Yazaki Y. Molecular mechanism of cardiaccellular hypertrophy by mechanical stress. J Mol Cell Cardiol 1995; 27: 133-40.
83. Sadoshima J, Izumo S. The cellular and molecular response ofcardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-71.
84. Wilson JM, Villareal RP, Hariharan R, Massumi A, Muthupillai R, Flamm SD. Magnetic resonance imaging of myocardial fibrosis inhypertrophic cardiomyopathy. Tex Heart Inst J 2002; 29: 176-80.
85. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989; 65: 657-70.
86. Buja LM, Willerson JT. The role of coronary artery lesions inischemic heart disease: insights from recent clinicopathologic, coronary arteriographic, and experimental studies. Hum Pathol 1987; 18: 451-61.
87. Shimizu M, Umeda K, Sugihara N, et al. Collagen remodelling inmyocardia of patients with diabetes. J Clin Pathol 1993; 46: 32-6.
88. Eghbali M. Cellular origin and distribution of transforming growthfactor-beta in the normal rat myocardium. Cell Tissue Res 1989; 256: 553-8.
89. Millan FA, Denhez F, Kondaiah P, Akhurst RJ. Embryonic geneexpression patterns of TGF beta 1, beta 2 and beta 3 suggest differentdevelopmental functions in vivo. Development 1991; 111: 131-43.
90. Brand T, Schneider MD. The TGF beta superfamily in myocardium:ligands, receptors, transduction, and function. J Mol CellCardiol 1995; 27: 5-18.
91. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation ofdiacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43: 1122-9.
92. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications:a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
93. Raimondi L, De Paoli P, Mannucci E, et al. Restoration of cardiomyocytefunctional properties by angiotensin II receptor blockadein diabetic rats. Diabetes 2004; 53: 1927-33.
94. Way KJ, Isshiki K, Suzuma K, et al. Expression of connectivetissue growth factor is increased in injured myocardium associatedwith protein kinase C beta2 activation and diabetes. Diabetes 2002; 51: 2709-18.
95. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruliof diabetic rats and glomerular mesangial cells cultured under highglucose conditions. Diabetes 1997; 46: 847-53.
96. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY. High glucoseinducedapoptosis in human endothelial cells is mediated by sequentialactivations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 2000; 101: 2618-24.
97. Liu W, Schoenkerman A, Lowe WL, Jr. Activation of members ofthe mitogen-activated protein kinase family by glucose in endothelialcells. Am J Physiol Endocrinol Metab 2000; 279: E782-90.
98. Fernyhough P, Gallagher A, Averill SA, et al. Aberrant neurofilamentphosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 1999; 48: 881-9.
99. Marshall CJ. Specificity of receptor tyrosine kinase signaling:transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-85.
100. Luo Z, Tzivion G, Belshaw PJ, Vavvas D, Marshall M, Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependentmechanism. Nature 1996; 383: 181-5.
101. Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD. Differentialtargeting of MAP kinases to the ETS-domain transcription factorElk-1. EMBO J 1998; 17: 1740-9.
102. Tanoue T, Adachi M, Moriguchi T, Nishida E. A conserved dockingmotif in MAP kinases common to substrates, activators andregulators. Nat Cell Biol 2000; 2: 110-6.
103. Dickens M, Rogers JS, Cavanagh J, et al. A cytoplasmic inhibitorof the JNK signal transduction pathway. Science 1997; 277: 693-6.
104. Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminalkinases and p38-mitogen-activated protein kinases in human heartfailure secondary to ischaemic heart disease. J Mol Cell Cardiol 1999; 31: 1429-34.
105. Remondino A, Kwon SH, Communal C, et al. Beta-adrenergicreceptor-stimulated apoptosis in cardiac myocytes is mediated byreactive oxygen species/c-Jun NH2-terminal kinase-dependent activationof the mitochondrial pathway. Circ Res 2003; 92: 136-8.
106. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet Cand gamma radiation. Duration of JNK activation may determinecell death and proliferation. J Biol Chem 1996; 271: 31929-36.
107. Seimiya H, Mashima T, Toho M, Tsuruo T. c-Jun NH2-terminalkinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 1997; 272: 4631-6.
108. Cahill MA, Peter ME, Kischkel FC, et al. CD95 (APO-1/Fas) inducesactivation of SAP kinases downstream of ICE-like proteases. Oncogene 1996; 13: 2087-96.
109. Kang SW, Adler SG, Lapage J, Natarajan R. p38 MAPK andMAPK kinase 3/6 mRNA and activities are increased in early diabeticglomeruli. Kidney Int 2001; 60: 543-52.
110. Strniskova M, Barancik M, Neckar J, Ravingerova T. Mitogenactivatedprotein kinases in the acute diabetic myocardium. MolCell Biochem 2003; 249: 59-65.
111. Dunlop ME, Muggli EE. Small heat shock protein alteration providesa mechanism to reduce mesangial cell contractility in diabetesand oxidative stress. Kidney Int 2000; 57: 464-75.
112. Mackay K, Mochly-Rosen D. Involvement of a p38 mitogenactivatedprotein kinase phosphatase in protecting neonatal rat cardiacmyocytes from ischemia. J Mol Cell Cardiol 2000; 32: 1585-8.
113. Communal C, Colucci WS, Singh K. p38 mitogen-activated proteinkinase pathway protects adult rat ventricular myocytes against beta adrenergic receptor- stimulated apoptosis. Evidence for Gidependentactivation. J Biol Chem 2000; 275: 19395-400.
114. Zhang H, Shi X, Hampong M, Blanis L, Pelech S. Stress-inducedinhibition of ERK1 and ERK2 by direct interaction with p38 MAPkinase. J Biol Chem 2001; 276: 6905-8.
115. Tobiume K, Matsuzawa A, Takahashi T, et al. ASK1 is requiredfor sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2001; 2: 222-8.
116. Takeda K, Hatai T, Hamazaki TS, Nishitoh H, Saitoh M, Ichijo H. Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiationand survival of PC12 cells. J Biol Chem 2000; 275: 9805-13.
117. Thandavarayan RA, Watanabe K, Ma M, et al. 14-3-3 proteinregulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol 2008; 75: 1797-806.
118. Xiang H, McNeill JH. Protein kinase C activity is altered in diabeticrat hearts. Biochem Biophys Res Commun 1992; 187: 703-10.
119. Koya D, King GL. Protein kinase C activation and the developmentof diabetic complications. Diabetes 1998; 47: 859-66.
120. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II anddiacylglycerol levels in the aorta and heart of diabetic rats: differentialreversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-63.
121. Guo M, Wu MH, Korompai F, Yuan SY. Upregulation of PKCgenes and isozymes in cardiovascular tissues during early stages ofexperimental diabetes. Physiol Genomics 2003; 12: 139-46.
122. Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression ofprotein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997; 94: 9320-5.
123. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heartcauses hypertrophy in adult mice and sudden death in neonates. JClin Invest 1997; 100: 2189-95.
124. Bowling N, Walsh RA, Song G, et al. Increased protein kinase Cactivity and expression of Ca2+-sensitive isoforms in the failinghuman heart. Circulation 1999; 99: 384-91.
125. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on thegene expression of transforming growth factor-beta, extracellularmatrix components, and prostanoids in the glomeruli of diabeticrats. J Clin Invest 1997; 100: 115-26.
126. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vasculardysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.
127. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerateddiabetic mesangial expansion by treatment with a PKC betainhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-47.
128. Idris I, Gray S, Donnelly R. Protein kinase C activation: isozymespecificeffects on metabolism and cardiovascular complications indiabetes. Diabetologia 2001; 44: 659-73.
129. Steinberg SF, Goldberg M, Rybin VO. Protein kinase C isoformdiversity in the heart. J Mol Cell Cardiol 1995; 27: 141-53.
130. Gurusamy N, Watanabe K, Ma M, et al. Glycogen synthase kinase3beta together with 14-3-3 protein regulates diabetic cardiomyopathy:effect of losartan and tempol. FEBS Lett 2006; 580: 1932-40.
131. Yin H, Chao L, Chao J. Adrenomedullin protects against myocardialapoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension 2004; 43: 109-16.
132. Enguita M, DeGregorio-Rocasolano N, Abad A, Trullas R. Glycogensynthase kinase 3 activity mediates neuronal pentraxin 1 expressionand cell death induced by potassium deprivation in cerebellargranule cells. Mol Pharmacol 2005; 67: 1237-46.
133. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc NatlAcad Sci USA 2002; 99: 907-12.
134. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediatedhypertension in the rat increases vascular superoxide production viamembrane NADH/NADPH oxidase activation. Contribution to alterationsof vasomotor tone. J Clin Invest 1996; 97: 1916-23.
135. Passier R, Zeng H, Frey N, et al. CaM kinase signaling inducescardiac hypertrophy and activates the MEF2 transcription factor invivo. J Clin Invest 2000; 105: 1395-406.
136. Yin H, Chao L, Chao J. Kallikrein/kinin protects against myocardialapoptosis after ischemia/reperfusion via Akt-glycogen synthasekinase-3 and Akt-Bad. 14-3-3 signaling pathways. J Biol Chem 2005; 280: 8022-30.
137. Tomita M, Mukae S, Geshi E, Umetsu K, Nakatani M, Katagiri T. Mitochondrial respiratory impairment in streptozotocin-induceddiabetic rat heart. Jpn Circ J 1996; 60: 673-82.
138. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabeticvascular complications. Diabetes Care 1996; 19: 257-67.
139. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrialsuperoxide production blocks three pathways of hyperglycaemicdamage. Nature 2000; 404: 787-90.
140. Kang YJ. Molecular and cellular mechanisms of cardiotoxicity. Environ Health Perspect 2001; 109 (Suppl 1): 27-34.
141. Alici B, Gumustas MK, Ozkara H, et al. Apoptosis in the erectiletissues of diabetic and healthy rats. BJU Int 2000; 85: 326-9.
142. Cai L, Chen S, Evans T, Deng DX, Mukherjee K, Chakrabarti S. Apoptotic germ-cell death and testicular damage in experimentaldiabetes: prevention by endothelin antagonism. Urol Res 2000; 28: 342-7.
143. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockadeprevents glucose-induced cardiac dysfunction in ventricularmyocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 2003; 42: 206-12.
144. Grimm D, Jabusch HC, Kossmehl P, et al. Experimental diabetesand left ventricular hypertrophy: effects of beta-receptor blockade. Cardiovasc Pathol 2002; 11: 229-37.
145. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hypertensiverats: optimizing blockade of the renin-angiotensin system. Clin Sci(Lond) 2003; 104: 341-7.
146. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediatingthe physiological and pathophysiological actions of angiotensinII in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-72.
147. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase:role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
148. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generatingNADH/NADPH oxidase system and regulates angiotensin IIinducedhypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271: 23317-21.
149. Campbell SE, Katwa LC. Angiotensin II stimulated expression oftransforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997; 29: 1947-58.
150. Baba HA, Iwai T, Bauer M, Irlbeck M, Schmid KW, Zimmer HG. Differential effects of angiotensin II receptor blockade on pressureinducedleft ventricular hypertrophy and fibrosis in rats. J Mol CellCardiol 1999; 31: 445-55.
151. Machackova J, Liu X, Lukas A, Dhalla NS. Renin-angiotensinblockade attenuates cardiac myofibrillar remodelling in chronicdiabetes. Mol Cell Biochem 2004; 261: 271-8.
152. Zaman AK, Fujii S, Goto D, et al. Salutary effects of attenuation ofangiotensin II on coronary perivascular fibrosis associated with insulinresistance and obesity. J Mol Cell Cardiol 2004; 37: 525-35.
153. Kim S, Wanibuchi H, Hamaguchi A, Miura K, Yamanaka S, Iwao H. Angiotensin blockade improves cardiac and renal complicationsof type II diabetic rats. Hypertension 1997; 30: 1054-61.
154. Hoenack C, Roesen P. Inhibition of angiotensin type 1 receptorprevents decline of glucose transporter (GLUT4) in diabetic ratheart. Diabetes 1996; 45 (Suppl 1): S82-7.
155. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensinconvertingenzyme inhibitors and angiotensin II receptor antagonists:beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-61.
156. Gillery P, Monboisse JC, Maquart FX, Borel JP. Glycation ofproteins as a source of superoxide. Diabete Metab 1988; 14: 25-30.
157. Craven PA, Phillips SL, Melhem MF, Liachenko J, DeRubertis FR. Overexpression of manganese superoxide dismutase suppresses increasesin collagen accumulation induced by culture of mesangialcells in high-media glucose. Metabolism 2001; 50: 1043-8.
158. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelialdysfunction in diabetes mellitus. Circ Res 2001; 88: E14-22.
159. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fattyacid stimulate reactive oxygen species production through proteinkinase C--dependent activation of NAD(P)H oxidase in culturedvascular cells. Diabetes 2000; 49: 1939-45.
160. Swain SD, Helgerson SL, Davis AR, Nelson LK, Quinn MT. Analysis of activation-induced conformational changes in p47phoxusing tryptophan fluorescence spectroscopy. J Biol Chem 1997; 272: 29502-10.
161. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxidegeneration by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-5.
162. Kojda G, Harrison D. Interactions between NO and reactive oxygenspecies: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-71.
163. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidativestress in human umbilical vein endothelial cells: the role ofprotein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52: 2795-804.